RxDoctor Payments Data

James Lee, MD

Family Medicine · Hamilton, TXNPI 1982695797

Payments from drug & device makers

$945in general payments, 2019–2025

Across 49 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$208
  • Amgen$127
  • Medtronic$115
  • Pfizer$57
  • Lilly USA, LLC$56
  • AbbVie$49
  • plus $333 from 12 others

What the payments were for

  • Travel & lodging$20822%
  • Food & beverage$73778%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$945 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$27,546
Medicare patients
121
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban191$106,824
EliquisApixaban165$102,875
OzempicSemaglutide89$98,291
MounjaroTirzepatide84$81,004
FarxigaDapagliflozin Propanediol108$62,890
OtezlaApremilast15$61,351
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt25$46,890
JanuviaSitagliptin Phosphate70$44,605
CreonLipase/Protease/Amylase14$32,292
Rufinamide27$30,628
MyrbetriqMirabegron56$25,266
JardianceEmpagliflozin28$25,110
TrulicityDulaglutide18$23,686
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$22,980
EntrestoSacubitril/Valsartan24$19,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$56$111,566137 claims
Johnson & JohnsonXarelto$15$106,824191 claims
Novo NordiskOzempic, Novolog$39$104,116118 claims
PfizerEliquis$57$102,875165 claims
AmgenOtezla$127$61,35115 claims
AbbVieCreon, Restasis, Namzaric, Linzess$49$58,15373 claims
MerckJanuvia, Janumet$44$50,87081 claims
GSKTrelegy Ellipta, Breo Ellipta$39$35,80550 claims
Astellas Pharma US IncMyrbetriq$46$25,26656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Hamilton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →